Trial Profile
An Open-label, Randomized Multicenter Study to Investigate the Anti-parasitic Activity, Pharmacokinetic and Safety of IM SAR97276A With Oral ACTs as Positive Control in Children Presenting With Symptomatic Plasmodium Falciparum Uncomplicated Malaria
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs SAR 97276 (Primary) ; Artemether/lumefantrine
- Indications Malaria
- Focus Therapeutic Use
- Sponsors Sanofi
- 20 May 2014 New trial record